In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 1856-1856
Abstract:
Statins are a class of drug that inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase that is the rate-limiting enzyme of cholesterols synthesis. Now, statins are among the most prescribed drug used for treatment of hypercholesterolemia by lower down the serum cholesterol concentration and it is also a major means to preventing and reducing the risk for cardiovascular diseases. In addition to prevent and treat cardiovascular diseases, the emerging evidences indicated the statins usage has a number of beneficial effect such as anti-inflammation and lowering down the risk of cancer. To investigate the anti-cancer effect statins drugs that have been approved to clinical usage we evaluated the inhibition of breast cancer and GBM cell line growth. Statins are also potent inhibitors to stem cell-like primary GBM cells freshly isolated from patients. Unexpected, statins treatment induces strong cell autophagy death signals as weak if not at all cellular apoptosis. Tumor cells can be rescued after statin treatment by adding intermediated product of cholesterol synthesis (mevalonate and GGPP), it indicates that the target of the statins is specifically related the cholesterols synthesis pathway. Knock-down the expression of geranylgeranyl pyrophosphate synthetase-1 (GGPS-1), another key enzyme in cholesterol synthesis pathway, also stimulated strong cell autophagy and cell death in vitro, also dramatically reduced U87 tumor growth in vivo. In vivo data also showed that directly injection of statin is better than oral administrate to delay GBM tumor growth. This study showed statins are potent anti-cancer drug in vitro and in animal model. These safe and well-tolerate drugs are good candidates for clinical test as cancer chemotherapy reagents. Citation Format: Pengfei Jiang, Rajesh Mukthavavam, Ying Chao, Natsuko Nomura, Valentina Fogal, Sandra Pastorino, Ila Summit, Santosh Kesari. Preclinical study for statins as anticancer drug. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1856. doi:10.1158/1538-7445.AM2013-1856 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2013-1856
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2013
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink
